The Lee et al. report also demonstrated similar rates of KRAS mutations (24.4%) in HER2-amplified CRC compared to our study (21.8%) and no BRAF mutations, similar to our study.12 While their report did not note any NRAS mutations, we noted an NRAS incidence of 3.4% in HER2-amplified CRC, likely detected due to the fact that our study represents a larger and multi-institutional patient population. This evidence concerns the gene ERBB2 and colorectal carcinoma.